Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2024-12-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
关于子公司GS1-144获得美国食品药品监督管理局新药临床试验申请默示许可的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Changchun High & New Technology Industry Group Co., Ltd. regarding its subsidiary's receipt of an implicit approval from the U.S. FDA for a new drug clinical trial application. It details the drug GS1-144, its intended clinical trial phase, and the potential impact and risks associated with the trial. The document is short (1245 characters) and serves as a regulatory announcement about a clinical trial approval rather than a financial report or detailed management discussion. It does not contain financial data, earnings, or detailed report content. It is an official announcement of a regulatory milestone relevant to investors. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-12-23 Chinese
关于控股子公司Ⅱ型单纯疱疹病毒mRNA疫苗临床试验申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Changchun High-tech Industry (Group) Co., Ltd. regarding the approval of a clinical trial application for an mRNA vaccine by its controlling subsidiary. It includes details about the approval notice, the vaccine, and the potential impact on the company. The document is short (1134 characters) and serves as an announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about clinical trial approval.
2024-12-20 Chinese
关于获得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (553 characters) about the company receiving a medical device registration certificate from a regulatory authority. It contains no financial data, no report or financial results, and no mention of shareholder meetings or voting. It is an official regulatory announcement about a product certification. The document is not a report, presentation, or financial filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2024-12-18 Chinese
关于债券持有人可转债持有比例变动达到10%暨股东持股比例变动超过1%的提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding changes in the holding proportions of convertible bonds and shareholders' equity. It details the conversion of bonds into shares, the resulting changes in shareholding percentages, and confirms that these changes do not affect the controlling shareholder or actual controller. The document includes specific data tables about bond holdings and shareholding changes. It is not a full financial report, earnings release, or management discussion. It is also not a notice of dividend, proxy solicitation, or merger activity. The document is a regulatory announcement about shareholding changes due to bond conversion, which fits the category of Major Shareholding Notification (MRQ). The document length is 2753 characters, which is relatively short but contains detailed shareholding change information, not just a brief notice or report publication announcement. Therefore, the best classification is MRQ with high confidence.
2024-12-18 Chinese
关于“高新定转”转股完成暨摘牌的公告
Delisting Announcement Classification · 95% confidence The document is an official announcement regarding the completion of conversion of a specific convertible bond ('高新定转') and its subsequent delisting from the Shenzhen Stock Exchange. It details the bond issuance, conversion terms, number of shares converted, and changes in share capital structure. The document is short (1661 characters) and focuses on the completion of bond conversion and the delisting of the bond from the exchange. This fits the definition of a Delisting Announcement (DLST), as it officially notifies the market about the bond's removal from trading. It is not a full financial report, earnings release, or management report, nor is it a regulatory filing or proxy material. Therefore, the correct classification is DLST with high confidence.
2024-12-18 Chinese
关于子公司GenSci122片临床试验申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Changchun High & New Technology Industries (Group) Co., Ltd. regarding the approval of a clinical trial application for a subsidiary's drug product GenSci122. It includes details about the drug, the approval from the National Medical Products Administration, and the potential impact and risks related to the clinical trial. The document is short (1166 characters) and is an announcement of an event (clinical trial approval) rather than a financial report or detailed regulatory filing. It does not contain financial data, management changes, voting results, or other report types. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-12-17 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.